JPMorgan Chase & Co. Sells 924,726 Shares of Smith & Nephew SNATS, Inc. $SNN

JPMorgan Chase & Co. reduced its stake in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) by 76.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 285,929 shares of the medical equipment provider’s stock after selling 924,726 shares during the quarter. JPMorgan Chase & Co.’s holdings in Smith & Nephew SNATS were worth $10,376,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. First Affirmative Financial Network purchased a new position in Smith & Nephew SNATS in the third quarter valued at about $208,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Smith & Nephew SNATS during the third quarter valued at about $41,000. NewEdge Advisors LLC boosted its holdings in shares of Smith & Nephew SNATS by 4,660.4% in the 3rd quarter. NewEdge Advisors LLC now owns 6,379 shares of the medical equipment provider’s stock valued at $231,000 after buying an additional 6,245 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Smith & Nephew SNATS in the 3rd quarter valued at about $672,000. Finally, United Capital Financial Advisors LLC purchased a new position in shares of Smith & Nephew SNATS in the 3rd quarter worth approximately $228,000. Institutional investors own 25.64% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Weiss Ratings reiterated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research note on Wednesday, January 21st. Canaccord Genuity Group raised their target price on shares of Smith & Nephew SNATS from $34.00 to $35.00 and gave the company a “hold” rating in a research note on Thursday, March 5th. Royal Bank Of Canada lowered shares of Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a report on Monday, December 15th. Finally, Wall Street Zen raised Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a research report on Sunday. One research analyst has rated the stock with a Strong Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $36.25.

Smith & Nephew SNATS Stock Performance

Shares of NYSE SNN opened at $31.69 on Friday. Smith & Nephew SNATS, Inc. has a fifty-two week low of $23.91 and a fifty-two week high of $38.79. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.57 and a quick ratio of 1.25. The business has a 50-day simple moving average of $34.29 and a two-hundred day simple moving average of $34.42.

Smith & Nephew SNATS (NYSE:SNN) last issued its quarterly earnings results on Tuesday, February 17th. The medical equipment provider reported $29.55 earnings per share for the quarter. The business had revenue of $1.60 billion for the quarter. On average, equities analysts forecast that Smith & Nephew SNATS, Inc. will post 1.69 EPS for the current year.

Smith & Nephew SNATS Announces Dividend

The business also recently announced a dividend, which will be paid on Wednesday, May 27th. Shareholders of record on Friday, March 27th will be given a dividend of $0.482 per share. This represents a yield of 304.0%. The ex-dividend date of this dividend is Friday, March 27th.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.